Skip to main content
Top
Published in: Current Urology Reports 10/2018

Open Access 01-10-2018 | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function

Author: C. R. Powell

Published in: Current Urology Reports | Issue 10/2018

Login to get access

Abstract

Purpose of Review

Sacral neuromodulation (SNM) is being used to treat lower urinary tract symptoms (LUTS) with growing popularity among clinicians in multiple specialties. As this therapy becomes more common in the USA and Europe, urologists will encounter more patients implanted with SNM generators.

Recent Findings

Over time, it has recently been understood that up to 53% will develop pain at the implant site as reported by Groen et al. (J Urol 186:954, 2011) and 3–38% will lose effective stimulation as reported by Al-zahrani et al. (J Urol 185:981, 2011) and White et al. (Urology 73:731, 2009). There is a paucity of troubleshooting methodology in the literature, apart from revision surgery, to salvage the SNM generator. In fact, it has been suggested that one contemporary series’ failure rate is lower than some historic series because of the ability to reprogram devices as reported by Siegel et al. (J Urol 199:229, 2018). Standard algorithms for such reprogramming efforts are lacking in the literature and may salvage some patients otherwise destined for surgical revision or addition of multimodal therapy to achieve acceptable symptom control.

Summary

It is possible to troubleshoot and thereby salvage many SNM generators, saving patients from surgical revision in many cases and increasing the number of patients with persistent benefit from SNM. The algorithms presented in this manuscript represent a systematic strategy for reprogramming and troubleshooting SNM generators.
Literature
1.
go back to reference Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.PubMed Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40.PubMed
2.
go back to reference Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65:79–95.CrossRefPubMed Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65:79–95.CrossRefPubMed
3.
go back to reference Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327.PubMed Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327.PubMed
4.
go back to reference Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63.CrossRefPubMed Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63.CrossRefPubMed
5.
go back to reference Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–40.PubMed Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–40.PubMed
6.
go back to reference •• Siegel S, Noblett K, Mangel J, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199:229. This 5-year prospective review of the contemporary SNM generator offers the most carefully described analysis of failures and reasons for revision. It demonstrates improvement over older series utilizing abdominally placed generators and leads sewn directly to the periosteum. CrossRefPubMed •• Siegel S, Noblett K, Mangel J, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199:229. This 5-year prospective review of the contemporary SNM generator offers the most carefully described analysis of failures and reasons for revision. It demonstrates improvement over older series utilizing abdominally placed generators and leads sewn directly to the periosteum. CrossRefPubMed
7.
go back to reference • Hijaz A, Vasavada SP, Daneshgari F, et al. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology. 2006;68:533. This single institution series does an excellent job of describing the types of failures and the reason for revision, as well as describing some efforts at salvaging failures using reprogramming. CrossRefPubMed • Hijaz A, Vasavada SP, Daneshgari F, et al. Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience. Urology. 2006;68:533. This single institution series does an excellent job of describing the types of failures and the reason for revision, as well as describing some efforts at salvaging failures using reprogramming. CrossRefPubMed
8.
go back to reference Shih C, Miller JL, Fialkow M, Vicars BG, Yang CC. Reoperation after sacral neuromodulation therapy: a single-institution experience. Female Pelvic Med Reconstr Surg. 2013;19:175–8.CrossRefPubMed Shih C, Miller JL, Fialkow M, Vicars BG, Yang CC. Reoperation after sacral neuromodulation therapy: a single-institution experience. Female Pelvic Med Reconstr Surg. 2013;19:175–8.CrossRefPubMed
9.
go back to reference Peeters K, Sahai A, De Ridder D, et al. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113:789–94.CrossRefPubMed Peeters K, Sahai A, De Ridder D, et al. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113:789–94.CrossRefPubMed
10.
go back to reference Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6.CrossRefPubMed Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6.CrossRefPubMed
11.
go back to reference van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol. 2006;49:366–72.CrossRefPubMed van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol. 2006;49:366–72.CrossRefPubMed
12.
go back to reference Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol. 2011;186:954–9.CrossRefPubMed Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol. 2011;186:954–9.CrossRefPubMed
13.
go back to reference White WM, Mobley JD 3rd, Doggweiler R, et al. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73:731–5.CrossRefPubMed White WM, Mobley JD 3rd, Doggweiler R, et al. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73:731–5.CrossRefPubMed
14.
go back to reference Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65–9.CrossRefPubMed Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65–9.CrossRefPubMed
15.
go back to reference • Rittenmeyer H. Sacral nerve neuromodulation (InterStim). Part III: case studies. Urol Nurs. 2008;28:26. Describes reprogramming SNM generators in great detail and although presented in case-report format, the reader unfamiliar with SNM programming will find this to be a good introduction and easy to read. PubMed • Rittenmeyer H. Sacral nerve neuromodulation (InterStim). Part III: case studies. Urol Nurs. 2008;28:26. Describes reprogramming SNM generators in great detail and although presented in case-report format, the reader unfamiliar with SNM programming will find this to be a good introduction and easy to read. PubMed
16.
go back to reference • Rittenmeyer H. Sacral nerve neuromodulation (InterStim). Part II: review of programming. Urol Nurs. 2008;28:21. Describes reprogramming SNM generators in great detail and although presented in case-report format, the reader unfamiliar with SNM programming will find this to be a good introduction and easy to read. PubMed • Rittenmeyer H. Sacral nerve neuromodulation (InterStim). Part II: review of programming. Urol Nurs. 2008;28:21. Describes reprogramming SNM generators in great detail and although presented in case-report format, the reader unfamiliar with SNM programming will find this to be a good introduction and easy to read. PubMed
17.
go back to reference Pettit P. Current opinion: complications and troubleshooting of sacral neuromodulation. Int Urogynecol J. 2010;21(Suppl 2):S491.CrossRefPubMed Pettit P. Current opinion: complications and troubleshooting of sacral neuromodulation. Int Urogynecol J. 2010;21(Suppl 2):S491.CrossRefPubMed
18.
go back to reference Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.CrossRefPubMed Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.CrossRefPubMed
19.
go back to reference Dwyer ME, Vandersteen DR, Hollatz P, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. Urology. 2014;84:911–8.CrossRefPubMed Dwyer ME, Vandersteen DR, Hollatz P, Reinberg YE. Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. Urology. 2014;84:911–8.CrossRefPubMed
20.
go back to reference Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol. 2006;175:2178–81.CrossRefPubMed Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol. 2006;175:2178–81.CrossRefPubMed
Metadata
Title
Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function
Author
C. R. Powell
Publication date
01-10-2018
Publisher
Springer US
Published in
Current Urology Reports / Issue 10/2018
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0837-5

Other articles of this Issue 10/2018

Current Urology Reports 10/2018 Go to the issue

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Approaches to Eliminate Radiation Exposure in the Management of Pediatric Urolithiasis

Urothelial Cancer (S Daneshmand, Section Editor)

Enhanced Endoscopy in Bladder Cancer

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Role of Angio-Embolization for Renal Cell Carcinoma

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Imaging Protocols for Active Surveillance in Renal Cell Carcinoma